

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/12, C07K 14/47, C12Q 1/68, G01N 33/50</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 98/07850</b> <b>(43) International Publication Date:</b> 26 February 1998 (26.02.98)
<b>(21) International Application Number:</b> PCT/EP97/04599 <b>(22) International Filing Date:</b> 22 August 1997 (22.08.97)  <b>(30) Priority Data:</b> 2,183,901 22 August 1996 (22.08.96) CA  <b>(71)(72) Applicants and Inventors:</b> BERGMANN, Johanna, E. [DE/DE]; Mörikestrasse 22, D-22587 Hamburg (DE). PREDDIE, Enrique, R. [CA/CA]; 4875 Dufferin Street, Montreal, Quebec H3X 2Z2 (CA).		<b>(81) Designated States:</b> AU, CH, CN, JP, NO, NZ, RU, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> AGENTS FOR PRE-SYMPTOMATIC DETECTION AND THERAPEUTIC TARGETING OF ALZHEIMER'S DISEASE AND DOWN SYNDROME IN HUMANS  <b>(57) Abstract</b>  Agents and methods for the diagnosis and therapy of Alzheimer's disease and the related condition Down syndrome are disclosed. Such agents include four genes located within the region of human chromosome 21 occupied by the APP gene, which are exclusively expressed in Alzheimer's disease or Down syndrome, respectively, the proteins encoded and expressed by these genes, the nucleic acid molecules influencing their expression, and endogenous antibodies produced in humans with Alzheimer's disease and Down syndrome against the above proteins. Also disclosed are antibodies and nucleotides to detect the presence of the proteins and nucleic acids in humans.		



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> C12N 15/12, 15/55, 9/64, C07K 14/47, C12Q 1/68, G01N 33/50, A61K 38/17, 38/46, C12N 15/85, C07K 14/705	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 98/07850</b> <b>(43) International Publication Date:</b> 26 February 1998 (26.02.98)
<b>(21) International Application Number:</b> PCT/EP97/04599 <b>(22) International Filing Date:</b> 22 August 1997 (22.08.97)  <b>(30) Priority Data:</b> 2,183,901 22 August 1996 (22.08.96) CA  <b>(71)(72) Applicants and Inventors:</b> BERGMANN, Johanna, E. [DE/DE]; Mörikestrasse 22, D-22587 Hamburg (DE). PREDDIE, Enrique, R. [CA/CA]; 4875 Dufferin Street, Montreal, Quebec H3X 2Z2 (CA).	<b>(81) Designated States:</b> AU, CH, CN, JP, NO, NZ, RU, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>With amended claims and statement.</i>  <b>(88) Date of publication of the international search report:</b> 17 September 1998 (17.09.98)  <b>Date of publication of the amended claims and statement:</b> 5 November 1998 (05.11.98)	
		<b>(54) Title:</b> AGENTS FOR PRE-SYMPTOMATIC DETECTION AND THERAPEUTIC TARGETING OF ALZHEIMER'S DISEASE AND DOWN SYNDROME IN HUMANS  <b>(57) Abstract</b>  Agents and methods for the diagnosis and therapy of Alzheimer's disease and the related condition Down syndrome are disclosed. Such agents include four genes located within the region of human chromosome 21 occupied by the APP gene, which are exclusively expressed in Alzheimer's disease or Down syndrome, respectively, the proteins encoded and expressed by these genes, the nucleic acid molecules influencing their expression, and endogenous antibodies produced in humans with Alzheimer's disease and Down syndrome against the above proteins. Also disclosed are antibodies and nucleotides to detect the presence of the proteins and nucleic acids in humans.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## AMENDED CLAIMS

[received by the International Bureau on 16 September 1998 (16.09.98);  
original claims 1-25 replaced by amended claims 1-10 (2 pages)]

(1) Specific ELISA methods for presymptomatic diagnosis of Downs syndrome in humans; this involves detecting, in extracts from human skin cells, serum, plasma and saliva, a Downs syndrome specific marker "DSAS", "SEQ ID:NO3" or the DSAS-containing protein "PAC", "SEQ ID:NO10".

(2) A specific ELISA method of claim 1 which detects endogenous antibodies produced in humans body fluids against DSAS, SEQ ID:NO3 and/or PAC, SEQ ID:NO10. The endogenous antibody is detected in all humans afflicted with Downs syndrome, in humans before any clinical symptoms of Downs symptoms appear and also in mothers carrying Downs syndrome babies.

(3) A method for preventing and treating Downs syndrome in humans that targets dsas, SEQ ID:NO1; pac, SEQ ID:NO9; DSAS, SEQ ID:NO3; PAC, SEQ ID:NO10; anti-DSAS endogenous antibody or anti-PAC endogenous antibody.

(4) Methods for presymptomatic diagnosis of all forms of Alzheimer's disease and clinically related conditions in humans that involve detecting in human cells, tissue and/or body fluids (serum, plasma, spinal fluid, saliva) mRNA, "alzas", SEQ ID:NO11 (specifically 204-241) or, mRNA "alzas1", SEQ ID:NO15 (specifically 55-156) or, mRNA "alzas2", SEQ ID:NO24 (specifically nucleotides 97-132).

(5) The method of claim 4 which detects the proteins "ALZASp", SEQ ID:NO12 expressed by alzas (SEQ ID:NO11) specifically amino acids 68 - 79 which are encoded by alzas nucleotides 204 - 241 or the protein "ALZAS1", SEQ ID:NO16 expressed by alzas1 (SEQ ID:NO15) specifically amino acid 20-51 which are encoded by alzas1 nucleotides 55-156 or "ALZAS2" (SEQ ID:NO25) expressed by alzas2 (SEQ ID:NO24) especially amino acids 33-44 which are encoded by alzas2 nucleotides 97-132.

(6) The amino acid sequences of claim 5 wherein these sequences are amino acid residues 68-79 from SEQ ID:NO11; amino acid residues 20-51 from SEQ ID:NO16 and amino acid residues 33-44 from SEQ ID:NO25.

(7) A method of claim 4 that detects an endogenous antibody produced in humans about to become afflicted or already afflicted with Alzheimer's disease, that is directed against epitopes within the amino acid residues of claim 6.

(8) Methods for preventing, controlling and treating Alzheimer's disease and other closely related clinical condition in humans that involve, blocking transcription of mRNA molecules from the group of claim 4 which have the sequence ID numbers SEQ ID:NO11, SEQ ID:NO15 and SEQ ID:NO24, specifically nucleotides 204-241, 55-156 and 97-132 respectively, or preventing the expression of or activity of the proteins of claims numbers 5 and 6, or preventing the activity of the endogenous antibodies of claim 7.

(9) A method of claim 5 which detects the proteins of the group "hyp1(ALZASP)" SEQ ID:NO13, "hyp2(ALZASp)" SEQ ID:NO14 and "hyp(ALZAS2)" SEQ ID:NO26 in humans about to be afflicted or afflicted with Alzheimer's disease or associated clinical conditions.

(10) The methods of claim 8 which involves preventing the expression or activity of the proteins of claim 9, and activity of the anti-endogenous antibody directed against these proteins when they are expressed in humans afflicted with Alzheimer's disease and closely related clinical conditions.



**STATEMENT UNDER ARTICLE 19**

In our view the amended claims have no significant impact on the description or the drawings of the present application; however, changes in the latter which might be deemed necessary by others will be done during the preliminary examination phase of the application. A copy of this letter and the amended claims are being sent simultaneously to the International Preliminary Examining Authority.

